# To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

> **NCT04281342** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Aprocitentan 25 mg
- **DRUG:** Aprocitentan 100 mg
- **DRUG:** Matching placebo
- **OTHER:** Moxifloxacin control to establish assay sensitivity

## Key facts

- **NCT ID:** NCT04281342
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-14
- **Primary completion:** 2021-08-03
- **Final completion:** 2021-09-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04281342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04281342, "To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04281342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*